Please select a Capability in order to start your service request.
Study to be Presented at the American Society of Human Genetics 2015 Annual Meeting Demonstrates Applications for High-Resolution Gene Expression StudiesOct 6, 2015
BALTIMORE and SAN JOSE, Calif., Oct. 6, 2015 – BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today launched its first dedicated product specifically for single cell genomics applications with BD FACSseq™, a high-throughput cell sorter designed for single cell genomic studies, combined with BD™ Precise Assays for single cell gene expression analysis. A poster demonstrating the performance of the BD FACSseq cell sorter and BD Precise Assays for targeted gene expression will be presented at the American Society of Human Genetics (ASHG) 2015 Annual Meeting. The BD FACSseq cell sorter and BD Precise Assays are currently for research use only.
Understanding the genomic differences of individual cell types provides unique insights into disease characteristics that have the potential to identify new approaches for developing targeted therapeutics. The BD FACSseq cell sorter combined with BD Precise Assays offers a high-throughput research method for single cell gene expression analysis to enable thousands of cells to be analyzed accurately, quickly, easily and affordably.
"Today, life science researchers require analysis of hundreds or thousands of single cells for single cell genomic studies,” said Stephen Gunstream, vice president of global genomics at BD. “The BD FACSseq cell sorter and BD Precise Assays provide an end to end solution for single cell analysis that automates cell selection and isolation, streamlines targeted enrichment, eliminates the need for expensive consumables or equipment, and simplifies downstream analysis."
The BD FACSseq cell sorter and BD Precise Assays will be on display at the ASHG exhibit hall in booth 419. Meeting attendees are also invited to attend a breakfast workshop on Oct. 8 at 7:30 a.m. at the Baltimore Convention Center, in Rooms 349/350, Level 3. To learn more, visit http://www.bdbiosciences.com/go/facsseq.
The BD FACSseq cell sorter will be available through unrestricted release in early 2016 worldwide.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.